Document is current
Any future updates will be listed below
-
Authors
Machado, Luiza S. https://orcid.org/0000-0001-8387-3832
Vidor, Pedro
Perquim, Lavínia
Limberger, Christian
Machado, Leonardo
Rocha, Andréia https://orcid.org/0000-0003-1567-3374
Soares, Carolina https://orcid.org/0000-0002-2338-4495
Rahmouni, Nesrine
S. Brum, Wagner https://orcid.org/0000-0002-9777-0559
Bellaver, Bruna
Ferreira, Pamela C. L. https://orcid.org/0000-0003-2134-9829
Borelli, Wyllians V. https://orcid.org/0000-0001-9282-0601
da Costa, Jaderson C.
Malpetti, Maura https://orcid.org/0000-0001-8923-9656
Pascoal, Tharick A.
Souza, Diogo O.
Edison, Paul https://orcid.org/0000-0002-6551-2002
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Ashton, Nicholas J.
Benedet, Andrea L.
Serrano-Pozo, Alberto
Rosa-Neto, Pedro https://orcid.org/0000-0001-9116-1376
Zimmer, Eduardo R. https://orcid.org/0000-0002-5349-0053
- License Information
-
More Information
Article History
Received: 8 October 2024
Revised: 10 July 2025
Accepted: 12 August 2025
First Online: 4 September 2025
Competing interests
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. AS-P reports on a material transfer agreement with Ionis Pharmaceuticals, Inc. PRN has served on the scientific advisory board of Novonordisk, Eisai, and Ely Lilly. He has also served as a consultant to Eisai, and Cerveau radiopharmaceuticals. ERZ has served on the scientific advisory board, as a consultant or speaker for Nintx, Novo Nordisk, Biogen, Lilly and Magdalena Biosciences. He is also a co-founder and a minority shareholder at masima. Other authors declare no conflict of interest.
